Jill Feldman: A must-attend educational session at ASCO24

Jill Feldman shared a post on X:

“Words couldn’t be more true – In the era of personalized care, the tumor is not the target! Thank you, Ramy Sedhom.
A must-attend educational session at ASCO24:
Fostering Equitable Supportive Care for Black Patients, Older Adults, and Patients with Prognostic Uncertainty.”

Read Further.
Source: Jill Feldman/X

Jill Feldman is a lung cancer patient and advocate. She is the Co-Founder EGFR Resisters, an advocacy group of EGFR positive lung cancer patients who are resistant to targeted treatment. She is the Past President of the LUNGevity Foundation, Deputy Chair of IASLC’s patient advisory board and a member of The Chicago Institute of Translational Medicine’s patient advisory board. Jill is committed to understanding and promoting patient-centered research as a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, as a planning committee member on IASLC’s North America Conference on Lung cancer and as a member of the the ECOG-ACRIN Research Group’s patient advocate committee and thoracic committee.